Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonafarnib +/- Ritonavir in Chronic Hepatitis Delta Virus (LOWR-5)
NCT02968641Phase 2Withdrawn
- Sponsor
- Eiger BioPharmaceuticals, Inc.
- Primary completion
- Feb 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of lonafarnib in hepatitis D (HDV), sponsored by Eiger BioPharmaceuticals, Inc.. Status: withdrawn.
02
Drugs
lonafarnib
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT02968641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968641.